Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-02

Clinical Trial Update: A Study Evaluating TRIV-509 in Atopic Dermatitis [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study evaluating TRIV-509 for atopic dermatitis, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRIV-509

Snippet

Sponsor: Triveni Bio | Conditions: Atopic Dermatitis | Phase 2 | Status: RECRUITING